vTv Therapeutics Inc. (VTVT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

vTv Therapeutics Inc. (VTVT) closed at USD 27.52 on 2026-10-14, a change of +31.7 % over the past year, with a market capitalization of USD 109.09M.

vTv Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

vTv Therapeutics Inc. key figures

Previous close

USD 27.52 (2026-10-14)

1-year change

+31.7 %

Market cap

USD 109.09M

Enterprise value

USD 256.15M

P/E ratio (trailing)

-38.32

P/E ratio (forward)

-6.30

EPS (trailing)

-0.72

EPS (forward)

-4.38

PEG ratio

n/a

Price to book

4.35

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.66

Employees

26

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About vTv Therapeutics Inc.

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for vTv Therapeutics Inc. and compare it with other stocks.